Patents by Inventor Paul H. Weinreb
Paul H. Weinreb has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150344553Abstract: Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.Type: ApplicationFiled: December 20, 2013Publication date: December 3, 2015Inventors: Paul H. Weinreb, Feng Chen, Ellen A. Garber, Jan Grimm, Fable Montrasio
-
Publication number: 20150315267Abstract: This disclosure relates to the use of anti-A? antibody or antigen-binding fragment thereof to reduce brain amyloid plaques, or minimizes the occurrence of microhemorrhage during chronic dosing of an anti-A? antibody or antigen-binding fragment thereof. For example, the disclosure relates to the method of reducing brain amyloid plaques, comprising administering to a subject an anti-A? antibody or antigen-binding fragment thereof that binds to the same epitope as BIIB037 antibody, wherein the administration can reduce amyloid plaques in brain without affecting vascular amyloid, and wherein BIIB037 antibody binds to an epitope comprising amino acids 3-6 of A?.Type: ApplicationFiled: December 6, 2013Publication date: November 5, 2015Inventors: Thierry Bussiere, Paul H. Weinreb, Thomas Engber, Kenneth Rhodes, Joseph Arndt, Fang Qian, Robert W. Dunstan, Shailendra Patel, Jan Grimm, Marcel Maier
-
Publication number: 20150140609Abstract: Monoclonal antibodies that specifically bind to M.96. Also included are methods of using these antibodies to treat mammals having or at risk of having 006-mediated diseases, or to diagnose % Q mediated diseases.Type: ApplicationFiled: July 28, 2014Publication date: May 21, 2015Inventors: Shelia M. Violette, Paul H. Weinreb, Kenneth J. Simon, Dean Sheppard, Diane R. Leone
-
Patent number: 8992924Abstract: The present invention is in the fields of cell biology, immunology and oncology. The invention provides humanized antibodies that recognize ?v?6 integrins, which antibodies comprise a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also provides methods for preparation of such antibodies, pharmaceutical compositions comprising them, and methods of treating, diagnosing and/or preventing various diseases and disorders by administering the humanized anti-?v?6 antibodies of the invention. The invention also relates to the identification of differential expression of the integrin ?v?6 on the surfaces of tumor cells and tissues, the use of this differential expression in determining the metastatic potential of tumor cells, and methods of diagnosis and treatment/prevention of tumor metastasis and for elimination of residual metastatic tumor cells using ligands, particularly antibodies, that bind to integrin ?v?6.Type: GrantFiled: May 17, 2011Date of Patent: March 31, 2015Assignee: Biogen Idec MA Inc.Inventors: Shelia M. Violette, Louise A. Koopman, Kenneth J. Simon, Paul H. Weinreb, Herman W. T. van Vlijmen, Jose W. Saldanha, Alexey A. Lugovskoy
-
Publication number: 20140294809Abstract: The present invention is in the fields of cell biology, immunology and oncology. The invention provides humanized antibodies that recognize ?v?6 integrins, which antibodies comprise a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also provides methods for preparation of such antibodies, pharmaceutical compositions comprising them, and methods of treating, diagnosing and/or preventing various diseases and disorders by administering the humanized anti-?v?6 antibodies of the invention. The invention also relates to the identification of differential expression of the integrin ?v?6 on the surfaces of tumor cells and tissues, the use of this differential expression in determining the metastatic potential of tumor cells, and methods of diagnosis and treatment/prevention of tumor metastasis and for elimination of residual metastatic tumor cells using ligands, particularly antibodies, that bind to integrin ?v?6.Type: ApplicationFiled: January 22, 2014Publication date: October 2, 2014Applicant: BIOGEN IDEC MA INC.Inventors: Shelia M. Violette, Louise A. Koopman, Kenneth J. Simon, Paul H. Weinreb, Herman W.T. Van Vlijmen, Jose W. Saldanha, Alexey A. Lugovskoy
-
Publication number: 20140227266Abstract: Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are Nogo receptor antagonist polynucleotides. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, nucleic acids encoding the same and antagonist polynucleotides.Type: ApplicationFiled: January 2, 2014Publication date: August 14, 2014Applicant: Biogen Idec MA Inc.Inventors: Daniel H.S. Lee, Dingyi Wen, R. Blake Pepinsky, Jane K. Relton, Xinzhong Wang, Alexey Lugovskoy, Werner Meier, Ellen A. Garber, Laura Silvian, Paul H. Weinreb
-
Patent number: 8669345Abstract: Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are Nogo receptor antagonist polynucleotides. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, nucleic acids encoding the same and antagonist polynucleotides.Type: GrantFiled: January 26, 2007Date of Patent: March 11, 2014Assignee: Biogen Idec MA Inc.Inventors: Daniel H. S. Lee, Dingyi Wen, R. Blake Pepinsky, Jane K. Relton, Xinzhong Wang, Alexey Lugovskoy, Werner Meier, Ellen A. Garber, Laura Silvian, Paul H. Weinreb
-
Publication number: 20120251532Abstract: Monoclonal antibodies that specifically bind to M.96. Also included are methods of using these antibodies to treat mammals having or at risk of having 006-mediated diseases, or to diagnose % Qmediated diseases.Type: ApplicationFiled: April 10, 2012Publication date: October 4, 2012Applicants: The Regents of the University of California, a California corporation, BIOGEN IDEC MA INC.Inventors: Shelia M. Violette, Paul H. Weinreb, Kenneth J. Simon, Dean Sheppard, Diane R. Leone
-
Patent number: 8153126Abstract: Monoclonal antibodies that specifically bind to ?v??. Also included are methods of using these antibodies to treat mammals having or at risk of having ?v?6-mediated diseases, or to diagnose ?V?6-mediated diseases.Type: GrantFiled: October 29, 2008Date of Patent: April 10, 2012Inventors: Shelia M. Violette, Paul H. Weinreb, Kenneth J. Simon, Dean Sheppard, Diane R. Leone
-
Publication number: 20110305629Abstract: The present invention is in the fields of cell biology, immunology and oncology. The invention provides humanized antibodies that recognize ?v?6 integrins, which antibodies comprise a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also provides methods for preparation of such antibodies, pharmaceutical compositions comprising them, and methods of treating, diagnosing and/or preventing various diseases and disorders by administering the humanized anti-?v?6 antibodies of the invention. The invention also relates to the identification of differential expression of the integrin ?v?6 on the surfaces of tumor cells and tissues, the use of this differential expression in determining the metastatic potential of tumor cells, and methods of diagnosis and treatment/prevention of tumor metastasis and for elimination of residual metastatic tumor cells using ligands, particularly antibodies, that bind to integrin ?v?6.Type: ApplicationFiled: May 17, 2011Publication date: December 15, 2011Applicant: BIOGEN IDEC MA INC.Inventors: Shelia M. Violette, Louise A. Koopman, Kenneth J. Simon, Paul H. Weinreb, Herman W.T. van Vlijmen, Jose W. Saldanha, Alexey A. Lugovskoy
-
Patent number: 7943742Abstract: The present invention is in the fields of cell biology, immunology and oncology. The invention provides humanized antibodies that recognize ?v?6 integrins, which antibodies comprise a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also provides methods for preparation of such antibodies, pharmaceutical compositions comprising them, and methods of treating, diagnosing and/or preventing various diseases and disorders by administering the humanized anti-?v?6 antibodies of the invention. The invention also relates to the identification of differential expression of the integrin ?v?6 on the surfaces of tumor cells and tissues, the use of this differential expression in determining the metastatic potential of tumor cells, and methods of diagnosis and treatment/prevention of tumor metastasis and for elimination of residual metastatic tumor cells using ligands, particularly antibodies, that bind to integrin ?v?6.Type: GrantFiled: July 10, 2006Date of Patent: May 17, 2011Assignee: Biogen Idec MA Inc.Inventors: Shelia M. Violette, Louise A. Koopman, Kenneth J. Simon, Paul H. Weinreb, Herman W. T. van Vlijmen, Jose W. Saldanha, Alexey A. Lugovskoy
-
Publication number: 20090186036Abstract: Monoclonal antibodies that specifically bind to M.96. Also included are methods of using these antibodies to treat mammals having or at risk of having O06-mediated diseases, or to diagnose % Qmediated diseases.Type: ApplicationFiled: October 29, 2008Publication date: July 23, 2009Applicants: Biogen Idec MA Inc., The Regents of the University of California, a California corporationInventors: Shelia M. Violette, Paul H. Weinreb, Kenneth J. Simon, Dean Sheppard, Diane R. Leone
-
Publication number: 20090099078Abstract: Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are Nogo receptor antagonist polynucleotides. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, nucleic acids encoding the same and antagonist polynucleotides.Type: ApplicationFiled: January 26, 2007Publication date: April 16, 2009Inventors: Daniel H.S. Lee, Dingyi Wen, R. Blake Pepinsky, Jane K. Relton, Xinzhong Wang, Alexey Lugovskoy, Werner Meier, Ellen A. Garber, Laura Silvian, Paul H. Weinreb
-
Publication number: 20090054632Abstract: Hydrophobically-modified proteins and methods of making them are described. A hydrophobic moiety is attached to a surface amino acid residue of the protein. The hydrophobic moiety can be a lipid or a peptide. Alternatively, the protein can be derivatized by a wide variety of chemical reactions that append a hydrophobic structure to the protein. The preferred protein is of mammalian origin and is selected from the group consisting of Sonic, Indian, and Desert hedgehog. The hydrophobic moiety is used as a convenient tether to which may be attached a vesicle such as a cell membrane, liposome, or micelle.Type: ApplicationFiled: August 20, 2007Publication date: February 26, 2009Applicants: Biogen Idec MA Inc., Curis, Inc.Inventors: R. Blake Pepinsky, Alphonse Galdes, Ellen A. Garber, Darren P. Baker, Jeffery A. Porter, Frederick R. Taylor, Kevin P. Williams, Russell C. Petter, Kathryn Strauch, Paul H. Weinreb, Dingyi Wen, Chenhui Zeng
-
Patent number: 7465449Abstract: Monoclonal antibodies that specifically bind to M.96. Also included are methods of using these antibodies to treat mammals having or at risk of having 006-mediated diseases, or to diagnose % Qmediated diseases.Type: GrantFiled: March 13, 2003Date of Patent: December 16, 2008Assignees: Biogen Idec MA Inc., The Regents of the University of CaliforniaInventors: Shelia M. Violette, Paul H. Weinreb, Kenneth J. Simon, Dean Sheppard, Diane R. Leone
-
Publication number: 20080286269Abstract: The present invention is in the fields of cell biology, immunology and oncology. The invention provides humanized antibodies that recognize ?v?6 integrins, which antibodies comprise a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also provides methods for preparation of such antibodies, pharmaceutical compositions comprising them, and methods of treating, diagnosing and/or preventing various diseases and disorders by administering the humanized anti-?v?6 antibodies of the invention. The invention also relates to the identification of differential expression of the integrin ?v?6 on the surfaces of tumor cells and tissues, the use of this differential expression in determining the metastatic potential of tumor cells, and methods of diagnosis and treatment/prevention of tumor metastasis and for elimination of residual metastatic tumor cells using ligands, particularly antibodies, that bind to integrin ?v?6.Type: ApplicationFiled: July 10, 2006Publication date: November 20, 2008Applicant: Biogen Idec MA.Inventors: Shelia M. Violette, Louise A. Koopman, Kenneth J. Simon, Paul H. Weinreb, Herman W.T. van Vlijmen, Jose W. Saldanha, Alexey A. Lugovskoy
-
Patent number: 6897297Abstract: Hydrophobically-modified proteins and methods of making them are described. A hydrophobic moiety is attached to a surface amino acid residue of the protein. The hydrophobic moiety can be a lipid or a peptide. Alternatively, the protein can be derivatized by a wide variety of chemical reactions that append a hydrophobic structure to the protein. The preferred protein is of mammalian origin and is selected from the group consisting of Sonic, Indian, and Desert hedgehog. The hydrophobic moiety is used as a convenient tether to which may be attached a vesicle such as a cell membrane, liposome, or micelle.Type: GrantFiled: May 26, 2000Date of Patent: May 24, 2005Assignees: Curis, Inc., Biogen Idec Inc.Inventors: R. Blake Pepinsky, Chenhui Zeng, Darren P. Baker, Dingyi Wen, Kevin P. Williams, Ellen A. Garber, Kathryn L. Strauch, Frederick R. Taylor, Paul H. Weinreb, Russell C. Petter, Alphonse Galdes, Jeffrey Porter